What does Palopegteriparatide (Yorvipath) do in plain English—and how does it work inside your body?
Palopegteriparatide is an FDA-regulated Parathyroid Hormone Analog (RxNorm RxCUI RXN-73362101-2599). Mechanistically, Delivered via 294 ug/.98mL Injection, Solution and 420 ug/1.4mL Injection, Solution (subcutaneous-route; NDC 73362-101, 73362-102), Palopegteriparatide mediates parathyroid hormone analog physiological effects manufactured/labeled by Ascendis Pharma, Endocrinology, Inc. with dose-dependent receptor occupancy and systemic clearance. [1][2].
When your doctor writes a prescription for Palopegteriparatide (RxNorm RxCUI RXN-73362101-2599, also dispensed under brand names including Yorvipath), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, Delivered via 294 ug/.98mL Injection, Solution and 420 ug/1.4mL Injection, Solution (subcutaneous-route; NDC 73362-101, 73362-102), Palopegteriparatide mediates parathyroid hormone analog physiological effects manufactured/labeled by Ascendis Pharma, Endocrinology, Inc. with dose-dependent receptor occupancy and systemic clearance. [2].
Across real-world patient logs on dotMD (92% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Palopegteriparatide tablet bottle and confirm with your pharmacist that it matches your prescribed strength (294 ug/.98mL Injection, Solution, 420 ug/1.4mL Injection, Solution, 168 ug/.56mL Injection, Solution).